Advantage eClinical	Cure Sickle Cell - eCli	nical		
SITENAME - (\$SITECODE)	<b>≜</b> \$USERNAME			
	Concor	nitant Medication (CM1)	Web Version: 1.0; 1.0	0.0800020
Segment (PROTSEG):A CM Number (CMSPID):			web version: 1.0, 1.0	U, UODEC2U
Only enter medications on this form take NOTE: Hydroxyurea treatment taken with	n on the day of enrollment. hin 30 days of enrollment is an exclusion o	riterion for this study.		
Medication:(CM1TRT)				
Start date:(CM1STDT)		7		
		(ddMMMyyyy) (CM1STES)	0-Exact date 3-Day only unknown 2-Day and month unknown rj 1-Day, month, and year unknown	
Indication:(CM1INDC)				
Stop date:(CM1ENDT)		,		

(CM1ONGO) 9-Ongoing

## Additional Selection Options for CM1

CM Number (CMSPID) (key field):

001-1 002-2 003-3 004-4 005-5 006-6 007-7 008-8 009-9 010-10 011-11 012-12 013-13 014-14 015-15 016-16 017-17 018-18 019-19 020-20 021-21 022-22 023-23 024-24 025-25 026-26 027-27 028-28 029-29 030-30 031-31 032-32 033-33 034-34 035-35 036-36 037-37 038-38 039-39 040-40 041-41 042-42 043-43 044-44 045-45 046-46 047-47 048-48 049-49

050-50

Advantage Cure Sickle Cell - eCl	inical
SITENAME - (\$SITECODE)	
D	emographics (DEM) Web Version: 1.0; 1.00; 08Dec20
Gender:(GENDER) Date of birth:(BIRTHDT)	M-Male F-Female (ddMMMyyyy)
Ethnicity-(ETHNIC)	1-Hispanic or Latino 2-Not Hispanic or Latino 3-Not reported 4-Unknown
Indicate No or Yes for each race listed below. Yes may be checked for more than Check this box if the participant refused to identify his or her race:( <i>RACEREF</i> ) American Indian or Alaskan Native:( <i>AMERIND</i> ) Asian:( <i>ASIAN</i> ) Native Hawaiian or other Pacific Islander:( <i>PACIFIC</i> ) Black or African American:( <i>BLACK</i> ) White:( <i>WHITE</i> ) Upon saving the screen, 'Race' will be populated based on the subject's response	1-Refused         N-No       Y-Yes         N-No       Y-Yes         N-No       Y-Yes         N-No       Y-Yes         N-No       Y-Yes         N-No       Y-Yes         N-No       Y-Yes
Race:(RACE)	00-UNKNOWN 99-MULTIPLE 01-AMERICAN INDIAN OR ALASKA NATIVE 02-ASIAN 03-NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER *Additional Options Listed Below

## Additional Selection Options for DEM

Race: 04-BLACK 05-WHITE

Advantage Cure Sickle Cell - eCl	inical						
eClinical							
■\$SITENAME - (\$SITECODE)							
	MAN01A (E	NR)				Web Versio	n: 1.0; 1.00; 08Dec2
Participant: (PATID)			(xxx-x)	(x-xxx)			
Enrollment date:(STARTDT)		(0	ddMMMyy	,			
Inclusion Criteria	1						
All answers in this section must be YES for the participant to be eligible. The Not which criteria were not assessed (i.e., evaluation discontinued once participant w	as identifie	d as ineliail	hle)		s who <u>fail to me</u>	et eligibility crit	t <u>eria</u> , to document
<ol> <li>Diagnosis of sickle cell disease with genotype HbSS, HbS/β<sup>0</sup> Thalassemia, HbSI or HbSO.(V101INC)</li> </ol>	D, 🔲 N-No	Y-Yes	A-No	t assessed			
2.Age 18-45 years (35-45 year-old patients must be followed at BCH).(V102INC)	N-No	Y-Yes	A-No	t assessed			
3. Receiving regularly-scheduled blood transfusions or exchange transfusions as		Y-Yes					
part of existing medical care.(V103INC) 4.Adequate hematologic parameters including: a. White blood cell (WBC) count within the range of 2.5 - 25.0 x 10 <sup>9</sup> /L	N-No	Y-Yes	A-No	t assessed			
b. Hemoglobin within the range of 7 - 11 g/dL							
c. Platelet count within the range of 150 - 700 x 10 <sup>9</sup> /L							
(V104INC) 5.Adequate organ function and performance status: a. Karnofsky performance status ≥70%	N-No	Y-Yes	A-No	t assessed			
b. Serum creatinine =1.5 times the upper limit of normal for age, and<br calculated creatinine clearence or GFR >/=60 mL/min/1.73m <sup>2</sup> .							
(V105INC)							
<ol> <li>Adequate venous access or an existing venous access device. (V106INC)</li> <li>Exclusion Criteria</li> </ol>	🔲 N-No	Y-Yes	🗌 A-No	t assessed			
All answers in this section must be NO for the participant to be eligible. The Not a				participants	who <u>fail to mee</u>	t eligibility crite	e <b>ria</b> , to document
which criteria were not assessed (i.e., evaluation discontinued once participant w 1.Participants who have uncontrolled illness including, but not limited to:		d as ineligil V-Yes		t assessed			
a. Ongoing or active infection.	- 11 110		- // 10				
<ul> <li>b. Emergency room admission or hospitalization for SCD-related reason i the past 30 days.</li> </ul>	in						
c. Major surgery in the past 30 days.							
d. Medical/psychiatric illness/social situations that would limit compliance with study requirements as determined by the treating physician.							
(V101EXC) 2.Known myelodysplasia of the bone marrow or abnormal bone marrow cytogenetics.(V102EXC)	N-No	Y-Yes	A-No	t assessed			
<ol> <li>Receipt of an investigational study drug or procedure within 90 days of study enrollment. (V103EXC)</li> </ol>	N-No	Y-Yes	A-No	t assessed			
4. Pregnant or breastfeeding. (V104EXC)		Y-Yes					
5.Known acute hepatitis or evidence of moderate or severe portal fibrosis or cirrhosis on prior biopsy.(V105EXC) 6.Known left ventricular ejection fraction <40%.(V106EXC)		Y-Yes					
<ol> <li>7.Known DLCO (corrected for hemoglobin), FEV1, and/or FVC &lt; 50% of predicted.</li> </ol>		<ul><li>Y-Yes</li><li>Y-Yes</li></ul>					
(V107EXC)							
8.ALT or AST > 2.5 X upper limit of normal or direct bilirubin > 2.0 mg/dL.(V108EX) 9.On hydroxyurea treatment.(V109EXC)		Y-Yes					
10.Requires placement of central line for apheresis.(V110EXC)		Y-Yes					
		03	_ // 140				

Advantage Cure Sickle Cell - eClinical							
SITENAME - (\$SITE	ECODE)	<b>≗</b> \$USERNAME					
		L	aboı	ratory Results (LAE	•)		
Segment (PROTSEG):A Visit Number (VISNO):							Web Version: 1.0; 1.00; 08Dec20
,	Baseline collection date:(LABBASDT)						
Were Baseline assessments performed?( <i>LABBASYN</i> ) If No, reason not done:( <i>LABBASNO</i> ) If Other, specify:( <i>LABBNOSP</i> )				1-Subject unable 2-Subject refusa 3-Technical prot 4-Clinic error 5-Laboratory err	l Ilem	• •	1
Chemistry	Ro	sult	Ev	pected Range			
Creatinine		ABCRRES) (x.x) mg/dl	_	3-1.7 mg/dl			
Aspartate Aminotransferase		ABASRES) (XX) u/L		40 u/L			
Alanine Aminotransferase (	(ALT) ( <i>LA</i>	ABALRES) (xx) u/L	3-3	30 u/L			
Bilirubin (direct)	(LA	ABBDRES) (x.x) mg/dl	0.0	)-0.4 mg/dl			
Bilirubin (total)	(LA	ABBTRES) (x.x) mg/dl	0.3	3-1.2 mg/dl			
Infectious Disease Marker Testing	g						
HIV 1 antigen (LA	BHIV1A) 🔲	0-Negative   1-Positive					
HIV 2 antigen (LA	BHIV2A) 🔲	0-Negative 1-Positive					
HBc core antigen (LA		-Negative 1-Positive					
HBV surface antigen (LA	BHBRES)	0-Negative 1-Positive					
HCV surface antibody (LA	BHCRES)	0-Negative 1-Positive					
		0-Negative 1-Positive					
		0-Negative 1-Positive					
,	,	0-Negative 1-Positive					
Day -7 Visit Assessments Day -7 collection date:(LABM					(ddMMMyyyy)		
Were Day -7 assessments p If No, reason not done: (LA		(LAB7ASYN)		1-Subject unable 2-Subject refuse 3-Technical prob 4-Clinic error 5-Laboratory err	res NA-N/A e to comply I lem		

If Other, specify:(LAB7NOSP)

Hemoglobin Electrophoresis

	Result	Expected Ra	ange
Total Hemoglobin	(LABHGTOT) (xx) g/dL	6-16 g/dL	
Hemoglobin A1 (HbA1)	(LABHGA1) (xx.x) %	95-97.9%	
Hemoglobin A2 (HbA2)	(LABHGA2) (X.X) %	2-3.5%	
Hemoglobin F (HbF)	(LABHGF) (X.X) %	0-2.1%	
Hemoglobin C (HbC)	(LABHGC) (xx) %	0-95%	
Hemoglobin S (HbS)	(LABHGS) (xx) %	0-95%	
Chemistry			
	Result		Expected Range
Lactic acid dehydrogenase	e (LDH) (LABLDH) (XX	xx) U/L	100-1000 U/L
Ferritin	(LABFTL) (X	<i>xxxx)</i> ng/mL	10-10,000 ng/mL
Pregnancy Test			
Was a pregnancy test perfo	, ,		N-No Y-Yes NA-N/A
If Yes, specimen type: (LA			U-Urine S-Serum
Specimen collection date	e:(LABPRGDT)		(ddMMMyyyy)
Result:(LABPGRES)			0-Negative 1-Positive
Day -1 Visit Assessments			
Day -1 collection date: (LAB			(ddMMMyyyy)
Were Day -1 assessments	• • •		N-No Y-Yes NA-N/A
If No, reason not done:(L	ABM1NO)		1-Subject unable to comply 2-Subject refusal 3-Technical problem 4-Clinic error 5-Laboratory error *Additional Options Listed Below
If Other, specify:(LAB1	NOSP)		
Blood Grouping ABO(LABABO)			,
Rh(LABRH)			N (Negative) P-+ (Positive)
Syphilis Antibody-Rapid Pla	asma Reagin (RPR) <i>(LABRPR)</i>		N-Negative R-Reactive
RBC Antibody screening(LA	ABRBC)		N-Negative P-Positive
Day 0 Visit Assessments			
Day 0 collection date: (LABI	D0DT)		(ddMMMyyyy)
Were Day 0 assessments	performed?(LAB0ASYN)		N-No Y-Yes NA-N/A
If No, reason not done:(L			1-Subject unable to comply 2-Subject refusal 3-Technical problem 4-Clinic error 5-Laboratory error *Additional Options Listed Below
If Other, specify:(LAB0	NOSP)		

PRE-Collection

CBC/Differential	F	Result	Expected Range
Hematocrit	(LABHEMA1)	(XX) %	20-51%
Reticulocytes	(LABRETC1)	(xx) %	0-30%
Platelets	(LABPLAT1)	(xxx) x10 <sup>3</sup> /microliter	100-750 x10 <sup>3</sup> /microliter
WBC	(LABWBC1)	(xx.x) x10 <sup>3</sup> /microliter	2.0-20.0 x10 <sup>3</sup> /microliter
Neutrophils (Abs)	(LABNEU1)	(xx) x10 <sup>3</sup> /microliter	1-10 x10 <sup>3</sup> /microliter
Lymphocytes (Abs)	(LABLYMP1)	(x) x10 <sup>3</sup> /microliter	1-5 x10 <sup>3</sup> /microliter
Basophils (Abs)	(LABBASO1)	(x) x10 <sup>3</sup> /microliter	0-2 x10 <sup>3</sup> /microliter
Eosinophils (Abs)	(LABEOSI1)	(x) x10 <sup>3</sup> /microliter	0-6 x10 <sup>3</sup> /microliter
Monocyte (Abs)	(LABMONO1)	(xx) x10 <sup>3</sup> /microliter	0-20 x10 <sup>3</sup> /microliter
Peripheral CD34+ count	(LABCD341)	(xxx) cells/microliter	0-200 cells/microliter
Start of Collection			
CBC/Differential	F	Result	Expected Range
Hematocrit	(LABHEMA2)	(XX) %	20-51%
Reticulocytes	(LABRETC2)	(xx) %	0-30%
		( )	
Platelets	(LABPLAT2)	(xxx) x10 <sup>3</sup> /microliter	100-750 x10 <sup>3</sup> /microliter
Platelets WBC	. ,		100-750 x10 <sup>3</sup> /microliter 2.0-20.0 x10 <sup>3</sup> /microliter
	(LABPLAT2)	(xxx) x10 <sup>3</sup> /microliter	
WBC	(LABPLAT2) (LABWBC2)	(xxx) $x10^{3}$ /microliter (xx.x) $x10^{3}$ /microliter	2.0-20.0 x10 <sup>3</sup> /microliter
WBC Neutrophils (Abs)	(LABPLAT2) (LABWBC2) (LABNEU2)	(xxx) x10 <sup>3</sup> /microliter (xx.x) x10 <sup>3</sup> /microliter (xx) x10 <sup>3</sup> /microliter	2.0-20.0 x10 <sup>3</sup> /microliter 1-10 x10 <sup>3</sup> /microliter
WBC Neutrophils (Abs) Lymphocytes (Abs)	(LABPLAT2) (LABWBC2) (LABNEU2) (LABLYMP2)	(xxx) $\times 10^3$ /microliter (xx.x) $\times 10^3$ /microliter (xx) $\times 10^3$ /microliter (x) $\times 10^3$ /microliter (x) $\times 10^3$ /microliter	2.0-20.0 x10 <sup>3</sup> /microliter 1-10 x10 <sup>3</sup> /microliter 1-5 x10 <sup>3</sup> /microliter
WBC Neutrophils (Abs) Lymphocytes (Abs) Basophils (Abs)	(LABPLAT2) (LABWBC2) (LABNEU2) (LABLYMP2) (LABLYMP2)	<ul> <li>(xxx) x10<sup>3</sup>/microliter</li> <li>(xx.x) x10<sup>3</sup>/microliter</li> <li>(xx) x10<sup>3</sup>/microliter</li> <li>(x) x10<sup>3</sup>/microliter</li> <li>(x) x10<sup>3</sup>/microliter</li> </ul>	2.0-20.0 $\times 10^{3}$ /microliter 1-10 $\times 10^{3}$ /microliter 1-5 $\times 10^{3}$ /microliter 0-2 $\times 10^{3}$ /microliter

## Additional Selection Options for LAB

**If No, reason not done:** 6-Investigator decision 99-Other

Adva eClinica	antage	Cure Sickle	Cell - eC	Clinical		
ssitename	- (\$SITECODE)	L \$USERNAME	:			
			CD	34 Negative Selection (NEG)		Web Version: 1.0; 1.01; 08Dec20
Segment (PROTSE) Visit Number (VISN)						wed version: 1.0; 1.01, 08Dec20
Visit Date:(NEGVIS	SDT)			(ddMMMyyyy)		
CD34 Negative Selecti	ion					
Name of sample pr	rocessor:(NEGPROC	)			(First Last)	
Total number of cel	lls processed:(NEGT	OTCL)		(xxx) x 10 <sup>6</sup> cell/mL		
% of CD34 negative	e cells in collection:(/	VEGCD34)		(xx) %		
(NEGFACSA)		plots available for upload	to eClinical?	N-No Y-Yes		
If Yes, were the p	plots uploaded?			N-No Y-Yes		
Select [Browse]	and choose the file yo	e] button at the bottom of ou intend to upload. Inclu D_NegSelect). Select [U	de a short			
Hematology		Result	E	xpected Range		
Platelets	(NEGPLT)	<i>(xxx)</i> x10 <sup>3</sup> /m	icroliter 10	00-750 x10 <sup>3</sup> /microliter		
WBC	(NEGWBC)	<i>(xx.x)</i> x10 <sup>3</sup>	<sup>3</sup> /microliter 2.	0-20.0 x10 <sup>3</sup> /microliter		

1-10 x10<sup>3</sup>/microliter

1-5 x10<sup>3</sup>/microliter

0-2 x10<sup>3</sup>/microliter

0-6 x10<sup>3</sup>/microliter

0-20 x10<sup>3</sup>/microliter

(xx)  $x10^3$ /microliter

(xx) x10<sup>3</sup>/microliter

(xx) x10<sup>3</sup>/microliter

(xx) x10<sup>3</sup>/microliter

(xx) x10<sup>3</sup>/microliter

Neutrophils (Abs)

Basophils (Abs)

Eosinophils (Abs)

Monocyte (Abs)

Lymphocytes (Abs) (NEGLYM)

(NEGANC)

(NEGBASO)

(NEGEOS)

(NEGMONO)

Advant eClinical	tage (	Cure Sickle Cell -	eClinical		
	SITECODE)	& \$USERNAME			
			CD34 Positive Selection (POS)		Web Version: 4 0: 1 01: 08Dec20
Segment (PROTSEG):A Visit Number (VISNO):					Web Version: 1.0; 1.01; 08Dec20
Visit Date:(POSVISDT)			(ddMMMyyyy)		
CD34 Positive Selection					
Name of sample proces	sor:(POSPROC)			(First Last)	
Total number of cells pro	cessed:(POSTOT	CL)	(xxx) x 10 <sup>6</sup> cell/mL		
% of CD34 positive cells	in collection:(POS	CD34)	(xx) %		
Are the CD34 positive s (POSFACSA)	election FACS plots	available for upload to eClinical	? N-No Y-Yes		
If Yes, were the plots	uploaded?		N-No Y-Yes		
Select [Browse] and c	hoose the file you i	utton at the bottom of the screen ntend to upload. Include a short PosSelect). Select [Upload].			
Hematology		Result	Expected Range		
Platelets	(POSPLT)	(xxx) x10 <sup>3</sup> /microliter	100-750 x10 <sup>3</sup> /microliter		
WBC	(POSWBC)	(xx.x) x10 <sup>3</sup> /microliter	2.0-20.0 x10 <sup>3</sup> /microliter		

1-10 x10<sup>3</sup>/microliter

1-5 x10<sup>3</sup>/microliter

0-2 x10<sup>3</sup>/microliter

0-6 x10<sup>3</sup>/microliter 0-20 x10<sup>3</sup>/microliter

(xx) x10<sup>3</sup>/microliter (xx) x10<sup>3</sup>/microliter

(xx) x10<sup>3</sup>/microliter

(xx) x10<sup>3</sup>/microliter

(xx) x10<sup>3</sup>/microliter

Neutrophils (Abs)

Basophils (Abs)

Eosinophils (Abs)

Monocyte (Abs)

Lymphocytes (Abs) (POSLYM)

(POSANC)

(POSBASO)

(POSEOS)

(POSMONO)

Advant eClinical	tage <sub>Cu</sub>	re Sickle Cell -	eClinical	_	
ssitename - (\$	SITECODE)	\$USERNAME			
egment ( <i>PROTSEG</i> ):A isit Number ( <i>VISNO</i> ):			Pre-CD34 Selection (PRE)		Web Version: 1.0; 1.01; 08Dec20
Visit Date:(PREVISDT)			(ddMMMyyyy)		
(PREFACSA) If Yes, were the plots To upload the plot, us Select [Browse] and c	essed:(PRETOTBV) llected:(PRETOTCL) pension:(PRECLSUS) collected:(PRECD34) tion FACS plots availat uploaded? e the [Upload file] butto thoose the file you inter	le for upload to eClinical? In at the bottom of the screer Ind to upload. Include a short Select). Select [Upload].		(First Last)	
Hematology		Result	Expected Range		
Hematocrit	(PREHCT)	(xx) %	20-51%		
Platelets	(PREPLT)	(xxx) x10 <sup>3</sup> /microliter	100-750 x10 <sup>3</sup> /microliter		
WBC	(PREWBC)	(xx.x) x10 <sup>3</sup> /microliter	2.0-20.0 x10 <sup>3</sup> /microliter		
Neutrophils (Abs)	(PREANC)	(xx) x10 <sup>3</sup> /microliter	1-10 x10 <sup>3</sup> /microliter		
Lymphocytes (Abs)	(PRELYM)	(xx) x10 <sup>3</sup> /microliter	1-5 x10 <sup>3</sup> /microliter		
Basophils (Abs)	(PREBASO)	(xx) x10 <sup>3</sup> /microliter	0-2 x10 <sup>3</sup> /microliter		
Eosinophils (Abs)	(PREEOS)	(xx) x10 <sup>3</sup> /microliter	0-6 x10 <sup>3</sup> /microliter		
Monocyte (Abs)	(PREMONO)	(xx) x10 <sup>3</sup> /microliter	0-20 x10 <sup>3</sup> /microliter		

Advantage Cure Sickle Cell - eCline	nical
□\$SITENAME - (\$SITECODE)	
Sickle	Collection Intake (SCI) Web Version: 1.0; 1.00; 08Dec20
Segment ( <i>PROTSEG</i> ):A Visit Number ( <i>VISNO</i> ):	
1.Visit date:(SCIVISDT)	(ddMMMyyyy)
Visit-Specific Information 2.Was the informed consent document signed and dated prior to any study procedures being performed?( <i>SCIICSD</i> ) Participant-Specific Information 3.Sickle Cell Disease Genotype:( <i>SCISCDG</i> )	N-No Y-Yes
3.Sickle Cell Disease Genotype:(SCISCDG)     4.Has the participant received chronic blood transfusions?(SCIBLTFX)	<ul> <li>1-HbSS</li> <li>2-HbSC</li> <li>3-HbSβ<sup>0-</sup> thalassemia</li> <li>4-HbSβ<sup>+-</sup> thalassemia</li> <li>5-HbSD</li> <li>N-No</li> <li>Y-Yes</li> </ul>
a.If Yes, how many transfusions have been received in the past 12 months? (SCITFNUM)	N-No     Y-Yes       (xx)     transfusions
5. How many vaso-occlusive events has the participant experienced in the past 12 months? (SCIVONUM)	(xx) events
<ul> <li>a.Number of these vaso-occlusive events which required narcotics or hospital admissions.(SCIVONHA)</li> </ul>	(xx) events
6.Has the participant had a splenectomy?(SCISPLEN)	N-No Y-Yes
a.If Yes, how was the procedure performed?(SCISPPER)	1-Laparoscopically 2-Surgically
7.Has the participant experienced any Central Nervous System (CNS) events? (SCICNSEV)	N-No Y-Yes
a.If Yes, indicate all CNS event(s) which have occurred:(SCISTROK)	1-Stroke (SCITIA) 1-Transient ischemic attack (SCISEIZR) 1-Seizures
1.If Other, specify:(SCICNSSP)	(SCICNSOT) 1-Other
8.Has the participant ever taken hydroxyurea (HU)?(SCIHU)	N-No Y-Yes
a.If Yes, did they respond to taking HU?(SCIHURES)	N-No Y-Yes
b.If Yes, are they presently taking HU?(SCIHUPR)	N-No Y-Yes
9.What is the highest the participant's Hemoglobin F (HgF) has been?(SCIHGF)	(xx) % (SCIHGUNK) 1-Unknown
10.Has the participant undergone a Red Cell Exchange in the past year?(SCIRCEX) a.If Yes, when?(SCIRCXDT)	N-No Y-Yes (dd/MM/yyyy)
Visit-Specific Screening Information	
11.Was blood drawn for screening hematology labs?(SCIBLDHE)	N-No Y-Yes
12.Was blood drawn for screening serology tests (HIV, HBV, and HCV)?(SCIBLDSE)	N-No Y-Yes
13. Female participants only: Was blood or urine collected for pregnancy testing? (N/A if female of nonchildbearing potential)(SCIPRTST) Medications/Protocol Deviations	1-No 2-Yes - blood 3-Yes - urine 4-N/A
14.Is the participant currently taking any medications? If Yes, submit a Concomitant Medications form.(SCIMEDYN) 15.Has there been a protocol deviation?(SCIPRDYN)	N-No Y-Yes
	IN-INU T-TES